Related references
Note: Only part of the references are listed.Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI
Chien-Hui Weng et al.
ONCOGENE (2019)
Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer
Zachary A. Yochum et al.
ONCOGENE (2019)
Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
Ayesha Murtuza et al.
CANCER RESEARCH (2019)
On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation
Benjamin P. Brown et al.
CLINICAL CANCER RESEARCH (2019)
Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy
Xiaofei Wang et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
Sha Zhao et al.
LUNG CANCER (2019)
114OPotential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ non-small cell lung cancer patients with primary resistance to osimertinib: A multicenter study
C Xu et al.
ANNALS OF ONCOLOGY (2019)
A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma.
Jonathan Daniel Schoenfeld et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
Silvia La Monica et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
Ciric To et al.
CANCER DISCOVERY (2019)
Osimertinib in Patients With T790M Mutation-Positive, Advanced Non-Small Cell Lung Cancer: Long-Term Follow-Up From a Pooled Analysis of 2 Phase 2 Studies
Myung-Ju Ahn et al.
CANCER (2019)
Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report
Yan Zhang et al.
ONCOTARGETS AND THERAPY (2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi et al.
NATURE COMMUNICATIONS (2019)
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
Viola W. Zhu et al.
LUNG CANCER-TARGETS AND THERAPY (2019)
Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer
C. Ricordel et al.
ANNALS OF ONCOLOGY (2018)
Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
Sun Min Lim et al.
CANCER TREATMENT REVIEWS (2018)
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients
Zhe Yang et al.
CLINICAL CANCER RESEARCH (2018)
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials
G. M. O'Kane et al.
CURRENT ONCOLOGY (2018)
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib
Jin Kang et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
Alexa B. Schrock et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC
Roberta Minari et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma
Liang Zeng et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib
Qi Zhang et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Acquired &ITEGFR&IT L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib
Yutao Liu et al.
LUNG CANCER (2018)
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy
R. Minari et al.
LUNG CANCER (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
Chia-Chi Lin et al.
LANCET RESPIRATORY MEDICINE (2018)
Taking advantage of drug resistance, a new approach in the war on cancer
Liqin Wang et al.
FRONTIERS OF MEDICINE (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC
Zofia Piotrowska et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Safety analysis of an open label, randomized phase 2 study of osimertinib alone versus osimertinib plus carboplatin-pemetrexed for patients with non-small cell lung cancer (NSCLC) that progressed during prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and which harbors a T790M mutation of EGFR.
Morihito Okada et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
Thanyanan Reungwetwattana et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).
Atsushi Nakamura et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition
Lei Deng et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Gonzalo Recondo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report
Jing Zhao et al.
ONCOTARGETS AND THERAPY (2018)
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion
Zofia Piotrowska et al.
CANCER DISCOVERY (2018)
A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group
Tao Jiang et al.
JOURNAL OF THORACIC DISEASE (2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard et al.
JAMA ONCOLOGY (2018)
1429PMolecular landscape of osimertinib resistance revealed by targeted panel sequencing and patient-derived cancer models in non-small cell lung cancer patients
M H Hong et al.
ANNALS OF ONCOLOGY (2018)
LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
V A Papadimitrakopoulou et al.
ANNALS OF ONCOLOGY (2018)
LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
S S Ramalingam et al.
ANNALS OF ONCOLOGY (2018)
Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Jana Fassunke et al.
NATURE COMMUNICATIONS (2018)
Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics
Ryosuke Okamura et al.
JCO PRECISION ONCOLOGY (2018)
With great power comes great vulnerability
Rodrigo Leite de Oliveira et al.
MOLECULAR & CELLULAR ONCOLOGY (2018)
Personalized therapy for lung cancer: Striking a moving target
Suchita Pakkala et al.
JCI INSIGHT (2018)
Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report
Yuri Taniguchi et al.
CASE REPORTS IN ONCOLOGY (2018)
Exploring the Resistance Mechanism of Osimertinib and Monitoring the Treatment Response Using Plasma ctDNA in Chinese NSCLC Patients
Y. Shi et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Xiuning Le et al.
CLINICAL CANCER RESEARCH (2018)
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component
James Chih-Hsin Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
June-Koo Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Silvia La Monica et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance
Zhen Wang et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR -Mutated Lung Cancer
Nir Peled et al.
Journal of Thoracic Oncology (2017)
Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR- Mutant Non–Small Cell Lung Cancer
Emily R. York et al.
Journal of Thoracic Oncology (2017)
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
Chao-Chi Ho et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer
Surein Arulananda et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib
A. Oztan et al.
LUNG CANCER (2017)
Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC
Franciele H. Knebel et al.
LUNG CANCER (2017)
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib
Sai-Hong Ignatius Ou et al.
LUNG CANCER (2017)
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
Collin M. Blakely et al.
NATURE GENETICS (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
Ken Uchibori et al.
NATURE COMMUNICATIONS (2017)
Tumor Evolution as a Therapeutic Target
Nabil Amirouchene-Angelozzi et al.
CANCER DISCOVERY (2017)
Overcoming resistance to third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer
Shoko Noda-Narita et al.
TRANSLATIONAL CANCER RESEARCH (2017)
Third-Generation Tyrosine Kinase inhibitors Targeting epidermal Growth Factor Receptor Mutations in non-Small Cell Lung Cancer
Tristan A. Barnes et al.
FRONTIERS IN ONCOLOGY (2017)
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
A. Martinez-Marti et al.
ANNALS OF ONCOLOGY (2017)
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer
Eiki Ichihara et al.
CANCER RESEARCH (2017)
Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.
James Chih-Hsin Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors
Shigenari Nukaga et al.
CANCER RESEARCH (2017)
EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance
Shuhang Wang et al.
CANCER LETTERS (2017)
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
Puyu Shi et al.
CANCER LETTERS (2016)
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Peter Ballard et al.
CLINICAL CANCER RESEARCH (2016)
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
Sandra Ortiz-Cuaran et al.
CLINICAL CANCER RESEARCH (2016)
CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer: apersonalized molecular surgical therapy
Huibin Tang et al.
EMBO MOLECULAR MEDICINE (2016)
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer
Geoffrey R. Oxnard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A Novel EGFRC797 Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay
Roopika Menon et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment
Jun Soo Ham et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC
Melissa Bersanelli et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
S7681 Mutation Mutation in EGFR in Patients with Lung Cancer
Konstantinos Leventakos et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Glenwood Goss et al.
LANCET ONCOLOGY (2016)
Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells
Yaqiong Tian et al.
ONCOLOGY RESEARCH (2016)
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Jacob J. Chabon et al.
NATURE COMMUNICATIONS (2016)
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
D. Planchard et al.
ANNALS OF ONCOLOGY (2015)
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
Catherine A. Eberlein et al.
CANCER RESEARCH (2015)
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
Matthew J. Niederst et al.
CLINICAL CANCER RESEARCH (2015)
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Dalia Ercan et al.
CLINICAL CANCER RESEARCH (2015)
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach
Julian Engel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas
Juliana Eng et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Mechanisms of Acquired Resistance to AZD9291 A Mutation-Selective, Irreversible EGFR Inhibitor
Tae Min Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Matthew J. Niederst et al.
NATURE COMMUNICATIONS (2015)
A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
Yuankai Shi et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation
Ken Takezawa et al.
CANCER DISCOVERY (2012)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
Stephanie Heon et al.
CLINICAL CANCER RESEARCH (2010)
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
Rafael Rosell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Binding of Ras to phosphoinositide 3-kinase p110α is required for Ras-driven tumorigenesis in mice
Surbhi Gupta et al.
CELL (2007)